Search

The prediction of asphalt mixture dynamic modulus (E*) was investigated based on 1128 E* measurements, using three regression and thirteen machine learning models. Asphalt binder properties and mixture volumetrics were characterized using the same feeding features in the NCHRP 1-37A Witczak model. However, three aggregate gradation characterization approaches were involved in both modelling techniques: the NCHRP 1-37A gradation parameters, Weibull distribution factors, and Bailey method parameters. This study evaluated the performance of these models based on various performance indicators, using both statistical and machine learning regression modeling techniques. K-fold cross-validation and learning curve analysis were conducted to assess the models' generalization capabilities. The conclusions of this study demonstrate the superiority of the ML models, particularly the Catboost ensemble learning regression (CbR). Hyperparameter optimization and residual analysis were performed to fine-tune and confirm the heteroscedasticity of the CbR model. The Bailey-based CbR model showed the highest coefficient of determination (R2) of 0.998 and the lowest root mean square error (RMSE) of 220 MPa. Moreover, SHAP values interpreted the CbR model and showed the relative importance of its feeding features. Based on the findings of this study, the CbR model is suggested to accurately predict E* for a variety of asphalt mixtures. This information can be used to improve pavement design and construction, leading to more durable and long-lasting pavements. [ABSTRACT FROM AUTHOR]

This research study aims to investigate the feasibility of incorporating high-density polyethylene waste (HDPEW) into bitumen applications. Two conventional conditions of bitumen, namely, aged bitumen (AB) and virgin bitumen (VB), are rejuvenated and modified, respectively, using post-consumer HDPEW sourced out of bottle crates. The outcome (Pyro oil, PO-HDPEW) of the pyrolysis thermochemical process is used by 10, 20, and 30% to rejuvenate AB, while the fine-ground granules (FG) (FG-HDPEW) are used by 2, 3, 4, and 5% to modify the VB with different percentages. Physical and rheological characterization testing, including penetration, softening point temperature, and rotational viscosity (RV), is conducted to evaluate the performance of the HDPEW-rejuvenated and -modified binders and optimize both rejuvenator and modifier percentages. In addition, physical and chemical tests, including scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDX), and Fourier transform infrared spectroscopy (FTIR) are conducted to analyze the composition, distribution of surface contaminants, and the molecular structure of the bitumen, based on their respective wavelengths. Moreover, advanced mechanical and rheological tests, including dynamic shear rheometer (DSR), multiple stress creep and recovery (MSCR), and linear amplitude sweep (LAS) tests, are conducted to investigate the susceptibility of the rejuvenated and modified bitumen with HDPEW to rutting and fatigue cracking. The testing results demonstrate that the addition of PO-HDPEW to AB and FG-HDPEW modification of VB can enhance the physical, chemical, mechanical, and rheological properties of bitumen; however, this study recommends further research on the aging performance of the PO-HDPEW-rejuvenated bitumen. This research provides insights into using HDPEW as a cost-effective and eco-friendly rejuvenator and modifier on bitumen properties, which can aid in the longevity and performance of pavements. [ABSTRACT FROM AUTHOR]

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults. Treatment is long and involves 2–3 years of a prolonged maintenance phase composed of oral chemotherapies. Adherence to these medications is critical to achieving good outcomes. However, adherence is difficult to determine, as there is currently no consensus on measures of adherence or criteria to determine nonadherence. Furthermore, there have been few studies in pediatric B-ALL describing factors associated with nonadherence. Thus, we performed a systematic review of literature on oral chemotherapy adherence during maintenance therapy in ALL following PRISMA guidelines. Published studies demonstrated various objective and subjective methods of assessing adherence without generalizable definitions of nonadherence. However, the results of these studies suggested that nonadherence to oral maintenance chemotherapy was associated with increased risk of relapse. Future studies of B-ALL therapy should utilize a uniform assessment of adherence and definitions of nonadherence to better determine the impact of nonadherence on B-ALL outcomes and identify predictors of nonadherence that could yield targets for adherence improving interventions. [ABSTRACT FROM AUTHOR]

Sickle cell disease (SCD) results in severe complications, such as anaemia and pain episodes. Hydroxyurea (HU) is efficacious in SCD, yet adherence remains low. To assess the relationship of HU adherence to health care utilization and patients' characteristics. This is a 5-year retrospective chart review. Patients' demographics and medical history were collected from the electronic medical record (EMR). HU adherence was evaluated using foetal haemoglobin "HbF%", mean corpuscular volume "MCV", and absolute neutrophil count "ANC". Age groups included children (<12 years), adolescents (12–17 years), and young adults (≥18 years). A total of 113 SCD patients on HU were included (median age 14 years, IQR 10–20; 50% female; 88% HbSS). Young adults had significantly higher HU adherence compared to adolescents and children, including higher median HbF% (24.2 vs. 12.4 vs. 8.6, p =.003), MCV (fl) (106.4 vs. 96.2 vs. 95.4, p =.01) and lower ANC (103/ml) (3.25 vs. 4.9 vs. 4.2, p =.01), respectively. Patients with chronic pain had lower HU adherence (HbF% 15.3 vs. 10.7, p =.04; ANC 3.6 vs. 6.3, p =.002; MCV 102.3 vs. 93.1, p =.1). Patients with higher HbF or MCV and lower ANC had significantly less frequent emergency room visits (rs=–0.26, p =.01; rs=–0.23, p =.01; rs=0.24, p =.01) and hospitalizations (rs=–0.27, p =.01; rs=–0.31, p =.01; rs=0.21, p =.02) as well as shorter length of stays (rs=–0.27, p =.0045; rs=–.34, p = 0.004; rs=0.23, p =.02), respectively. Similar trends in HU adherence and health care utilization were seen in subgroup analysis of only HbSS patients. There was no significant association of HU adherence to patients' sex, socio-economic status, distance from hospital, and HU duration. Young adults with SCD had significantly higher HU adherence compared to children and adolescents. Patients with lower HU adherence and/or chronic pain had increased health care utilization. Future studies examining barriers to adherence and evaluating interventions to optimize HU adherence in SCD are warranted. Young adults with SCD had significantly higher HU adherence, as reflected in their laboratory markers, compared to children and adolescents. Patients with higher HU adherence and/or those without chronic pain had lower or less frequent health care utilization. No significant association of HU adherence to patients' sex, socio-economic status and distance from hospital. [ABSTRACT FROM AUTHOR]

Iron chelation therapy (ICT) is essential to prevent complications of iron overload in patients with transfusion-dependent thalassaemia. However, there is currently no standard for how to best measure adherence to ICT, nor what level of adherence necessitates concern for poor outcomes, especially in paediatric patients. The objectives of this review are to identify rates of adherence to ICT, predictors of adherence, methods of measurement, and adherence-related health outcomes in children and adolescents. This review covers the literature published between 1980 and 2020 on ICT in thalassaemia that assessed adherence or compliance. Included studies reflect original research. The preferred reporting items of systematic reviews and meta-analyses (PRISMA) guidelines were followed for reporting results, and the findings were critically appraised with the Oxford Centre for Evidence-based Medicine criteria. Of the 543 articles, 37 met the inclusion criteria. The most common methods of assessing adherence included patient self-report (n = 15/36, 41.7%), and pill count (n = 15/36, 41.7%), followed by subcutaneous medication monitoring (5/36, 13.8%) and prescription refills (n = 4/36, 11.1%). Study sizes ranged from 7 to 1115 participants. Studies reported adherence either in "categories" with different levels of adherence (n = 29) or "quantitatively" as a percentage of medication taken out of those prescribed (n = 7). Quantitatively, the percentage of adherence varied from 57% to 98.4% with a median of 89.5%. Five studies focussed on interventions, four of which were designed to improve adherence. Studies varied in sample size and methods of assessment, which prohibited performing a meta-analysis. Due to a lack of clinical consensus on how adherence is defined, it is difficult to compare adherence to ICT in different studies. Future studies should be aimed at creating guidelines for assessing adherence and identifying suboptimal adherence. These future efforts will be crucial in informing evidence-based interventions to improve adherence and health outcomes in thalassaemia patients. Predictive factors associated with ICT adherence in the paediatric population include age, social perception of ICT, social support, and side effects/discomfort. Increased adherence in the paediatric population is associated with decreased serum ferritin and improved cardiac, hepatic, and endocrine outcomes. Inadequate adherence to ICT is associated with increased lifetime health costs. There are few studies that focussed on interventions to increase adherence in the paediatric population, and the studies that do exist all focussed on different types of interventions; successful interventions focussed on consistent, long-term engagement with patients. [ABSTRACT FROM AUTHOR]

Sickle-cell disease (SCD) is an inherited hemoglobinopathy, causing lifelong complications such as painful vaso-occlusive episodes, acute chest syndrome, stroke, chronic anemia, and end-organ damage, with negative effects on quality of life and life expectancy. Within the last five years, three new treatments have been approved: L-glutamine in 2017 and crizanlizumab and voxelotor in 2019. We conducted a literature search of these three medications, and of the 31 articles meeting inclusion criteria, 6 studied L-glutamine, 9 crizanlizumab, and 16 voxelotor. Treatment with L-glutamine was associated with decrease in pain crises, hospitalizations, and time to first and second crises, with a decrease in RBC transfusion rate. Barriers to filling and taking L-glutamine included insurance denial, high deductible, and intolerability, especially abdominal pain. Crizanlizumab was associated with a reduction in pain crises and time to first crisis, with reduction in need for opioid use. Adverse effects of crizanlizumab include headache, nausea, insurance difficulty, and infusion reactions. Voxelotor was associated with increased hemoglobin and decreased markers of hemolysis. Barriers for voxelotor use included insurance denial and side effects such as headache, rash, and diarrhea. These three medications represent exciting new therapies and are generally well-tolerated though price and insurance approval remain potential barriers to access. Other studies are ongoing, particularly in the pediatric population, and more real-world studies are needed. The objective of this article is to evaluate post-approval studies of crizanlizumab, voxelotor, and L-glutamine in SCD, with a focus on real-world efficacy, side effects, and prescribing data. [ABSTRACT FROM AUTHOR]

Background: Hydroxyurea therapy is effective for reducing complications related to sickle cell disease (SCD) and is recommended by National Health Lung and Blood Institute care guidelines. However, hydroxyurea is underutilized, and adherence is suboptimal. We wanted to test a multilevel mobile health (mHealth) intervention to increase hydroxyurea adherence among patients and improve prescribing among providers in a multicenter clinical trial. In the first 2 study sites, participants were exposed to the early phases of the COVID-19 pandemic, which included disruption to their regular SCD care. Objective: We aimed to describe the impact of the COVID-19 pandemic on the implementation of an mHealth behavioral intervention for improving hydroxyurea adherence among patients with SCD. Methods: The first 2 sites initiated enrollment 3 months prior to the start of the pandemic (November 2019 to March 2020). During implementation, site A clinics shut down for 2 months and site B clinics shut down for 9 months. We used the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework to evaluate the implementation and effectiveness of the intervention. mHealth implementation was assessed based on patients' daily app use. Adherence to hydroxyurea was calculated as the proportion of days covered (PDC) from prescription records over the first 12 and 24 weeks after implementation. A linear model examined the relationship between app usage and PDC change, adjusting for baseline PDC, lockdown duration, and site. We conducted semistructured interviews with patients, health care providers, administrators, and research staff to identify factors associated with mHealth implementation and effectiveness. We used a mixed methods approach to investigate the convergence of qualitative and quantitative findings. Results: The percentage of patients accessing the app decreased after March 15, 2020 from 86% (n=55) to 70% (n=45). The overall mean PDC increase from baseline to week 12 was 4.5% (P=.32) and to week 24 was 1.5% (P=.70). The mean PDC change was greater at site A (12 weeks: 20.9%; P=.003; 24 weeks: 16.7%; P=.01) than site B (12 weeks: -8.2%; P=.14; 24 weeks: -10.3%; P=.02). After adjustment, PDC change was 13.8% greater in those with increased app use after March 15, 2020. Interview findings indicated that site B's closure during COVID-19 had a greater impact, but almost all patients reported that the InCharge Health app helped support more consistent medication use. Conclusions: We found significant impacts of the early clinic lockdowns, which reduced implementation of the mHealth intervention and led to reduced patient adherence to hydroxyurea. However, disruptions were lower among participants who experienced shorter clinic lockdowns and were associated with higher hydroxyurea adherence. Investigation of added strategies to mitigate the effects of care interruptions during major emergencies (eg, patient coaching and health navigation) may "insulate" the implementation of interventions to increase medication adherence. [ABSTRACT FROM AUTHOR]

One of the main difficulties with employing recycled asphalt pavement (RAP) in hot mix asphalt (HMA) is bitumen aging; hence, the percentage of RAP in the HMA is limited. This research evaluates the rheological properties of the RAP binder and the performance of HMA containing high RAP content using waste engine oil (WEO) from an Electrical Power Plant as a rejuvenator. The rheological and microstructural properties of the RAP binder and rejuvenated RAP binder were determined in the laboratory. Both the recycled and rejuvenated recycled mixes were tested for Marshall stability, indirect tensile strength, dynamic modulus (E*), and flow number tests. The RAP binder was recovered using two different processes: rotavapor distillation followed by centrifugation (RCRD) and column distillation without centrifugation (RNCCD). The optimal WEO percentages for the RCRD and RNCCD recovery procedures were 0.5% and 3%, respectively. The Marshall test results revealed that adding WEO to the recycled mix enhanced its stability and flow compared to the control mix. The rejuvenated mix containing recovered binder from the RCRD recovery process was found to be better than the rejuvenated mix containing recovered binder from the RNCCD recovery process. The rejuvenated recycled mixes outperformed the recycled mix in terms of moisture resistance, which was evidenced by tensile strength ratio values of 0.88, 0.90, and 0.91 for the control and 0.5% and 3% WEO modified mixes, respectively. Finally, the results of dynamic modulus and flow number testing revealed that the rejuvenated mixes had a modest drop in both the dynamic modulus and flow number compared to the non-rejuvenated mix. [ABSTRACT FROM AUTHOR]

Sickle cell disease (SCD) is a lifelong burdensome disorder of heterogenic expression. This study investigated the longer-term economic burden of severe presentation of SCD. As SCD treatment landscapes evolve toward curative intent gene therapies, understanding how SCD-associated costs may change over the patient lifetime will be important for medical decision-making. Patients with severe presentation of SCD (presence of acute vaso-occlusive events [VOEs] or history of stroke and/or other disease-related sequelae), were identified within the MarketScan Commercial and Medicare Supplemental and Multi-state Medicaid Databases from 1/1/2010 to 12/31/2018. The first SCD claim served as the index date and patients were followed over a 5-year post-period. Clinical characteristics and healthcare resource utilization and costs were assessed over follow-up for eligible cohorts of commercial and Medicaid patients with severe SCD presentation and age-based subgroups (<18, 18–30, and ≥31). A total of 4,487 patients, primarily insured via Medicaid (79.2%), qualified for the analysis. Patients evidenced persistent VOEs over follow-up; prevalence of most comorbidities increased with age. Mean total healthcare costs over the 5-year follow-up were $275,143 (SD± $406,770) and $362,728 (SD± $620,189) in the commercial and Medicaid samples, respectively. Disease severity, assessed by the number of VOEs and utilization of inpatient and emergency services, peaked in the 18–30 year group in both samples. These groups also evidenced the highest mean healthcare costs over the 5-year follow-up at $344,776 (SD± $434,521) and $671,321 (SD± $938,764) in the commercial and Medicaid samples respectively. Results indicate high clinical need and economic burden among patients with severe presentation of SCD. These findings not only highlight the need for improved therapeutic options to limit or prevent disease progression, but also start to provide insight on lifetime costs of SCD that will be needed in the evaluation of emerging curative intent therapies. [ABSTRACT FROM AUTHOR]

Background: eHealth tools such as patient portals and personal health records, also known as patient-centered digital health records, can engage and empower individuals with chronic health conditions. Patients who are highly engaged in their care have improved disease knowledge, self-management skills, and clinical outcomes. Objective: We aimed to systematically review the effects of patient-centered digital health records on clinical and patient-reported outcomes, health care utilization, and satisfaction among patients with chronic conditions and to assess the feasibility and acceptability of their use. Methods: We searched MEDLINE, Cochrane, CINAHL, Embase, and PsycINFO databases between January 2000 and December 2021. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eligible studies were those evaluating digital health records intended for nonhospitalized adult or pediatric patients with a chronic condition. Patients with a high disease burden were a subgroup of interest. Primary outcomes included clinical and patient-reported health outcomes and health care utilization. Secondary outcomes included satisfaction, feasibility, and acceptability. Joanna Briggs Institute critical appraisal tools were used for quality assessment. Two reviewers screened titles, abstracts, and full texts. Associations between health record use and outcomes were categorized as beneficial , neutral or clinically nonrelevant , or undesired. Results: Of the 7716 unique publications examined, 81 (1%) met the eligibility criteria, with a total of 1,639,556 participants across all studies. The most commonly studied diseases included diabetes mellitus (37/81, 46%), cardiopulmonary conditions (21/81, 26%), and hematology-oncology conditions (14/81, 17%). One-third (24/81, 30%) of the studies were randomized controlled trials. Of the 81 studies that met the eligibility criteria, 16 (20%) were of high methodological quality. Reported outcomes varied across studies. The benefits of patient-centered digital health records were most frequently reported in the category health care utilization on the "use of recommended care services" (10/13, 77%), on the patient-reported outcomes "disease knowledge" (7/10, 70%), "patient engagement" (13/28, 56%), "treatment adherence" (10/18, 56%), and "self-management and self-efficacy" (10/19, 53%), and on the clinical outcome "laboratory parameters," including HbA1c and low-density lipoprotein (LDL; 16/33, 48%). Beneficial effects on "health-related quality of life" were seen in only 27% (4/15) of studies. Patient satisfaction (28/30, 93%), feasibility (15/19, 97%), and acceptability (23/26, 88%) were positively evaluated. More beneficial effects were reported for digital health records that predominantly focus on active features. Beneficial effects were less frequently observed among patients with a high disease burden and among high-quality studies. No unfavorable effects were observed. Conclusions: The use of patient-centered digital health records in nonhospitalized individuals with chronic health conditions is potentially associated with considerable beneficial effects on health care utilization, treatment adherence, and self-management or self-efficacy. However, for firm conclusions, more studies of high methodological quality are required. Trial Registration: PROSPERO (International Prospective Register of Systematic Reviews) CRD42020213285; https://www.crd.york.ac.uk/prospero/display%5frecord.php?RecordID=213285 J Med Internet Res 2022;24(12):e43086 doi:10.2196/43086 [ABSTRACT FROM AUTHOR]

Flexible pavement structure design is a complex task because of the variability of design input parameters and complex failure mechanisms. Therefore, the aim of this study is to develop and implement a simplified Mechanistic-Empirical (M-E) pavement design method based on the 1993 American Association of State Highway and Transportation Officials (AASHTO), the National Cooperative Highway Research Program (NCHRP) 9-22, and NCHRP 1-37A and 1-40D projects. This simplified methodology is implemented into a computer code and a user-friendly software called "ME-PAVE". In this methodology, only two equivalent temperatures, as per the NCHRP 9-22 project, are estimated to adjust the dynamic modulus of the asphalt layer(s) for Asphalt Concrete (AC) rutting and AC fatigue cracking prediction instead of using the hourly climatic data, as in the AASHTOWare Pavement ME. In ME-PAVE, the structural responses at critical locations in the pavement structure are determined by a Finite Element Module (FEM), which is verified by a Multi-layer Elastic Analysis (MLEA) program. To ensure that the simplified methodology is practical and accurate, the incorporated transfer functions in the proposed simplified methodology are calibrated based on the Long-Term Pavement Performance (LTPP) data. Based on statistical analyses, the built-in FEM results exhibit very similar trends to those yielded by MLEA, with a coefficient of determination, R2 of 1.0. For all practical purposes, the proposed methodology, despite all simplifications, yields acceptable prediction accuracy with R2 of 0.317 for the rut depth compared to the current practices, NCHRP 1-37A and 1-40D (R2 = 0.399 and 0.577, respectively); while the prediction accuracy for fatigue cracking with R2 of 0.382 is comparable to the NCHRP 1-40D with R2 of 0.275. Nonetheless, the standard error for both distresses is in good agreement based on the investigated data and the developed methodology. Finally, the conducted sensitivity analysis demonstrate that the proposed methodology produces rational pavement performance. [ABSTRACT FROM AUTHOR]

There are no agreed upon terminology to define "refractory" pediatric Immune Thrombocytopenia (ITP). Guidelines are therefore limited to arbitrary and outdated definitions. The Pediatric ITP Consortium of North America held a meeting in 2023 to define this entity. With 100% agreement, the faculty established that pediatric ITP that is refractory to emergent therapy could be defined as no platelet response after treatment with all eligible emergent pharmacotherapies. With 100% agreement, the working group established that pediatric patients with ITP that continue to demonstrate high disease burden and/or no platelet response despite treatment with multiple classes of disease modifying therapies represent a challenging subset of ITP. These patients are at higher risk of ongoing disease burden and merit additional investigation as well as consideration for clinical trials or novel therapies. Future efforts to define disease burden and disease response will be completed in collaboration with the ITP International Working Group., (Copyright © 2024 American Society of Hematology.)